Side Effects of Pulmozyme

Patients taking Pulmozyme have experienced the following side effects

  • Change in or loss of voice

  • Throat discomfort

  • Red, watery eyes

  • Rash 

  • Runny nose

  • Lower lung function

  • Indigestion

  • Shortness of breath

  • Mild to moderate hives

  • Fever

  • Chest pain

Mild to moderate hives and mild skin rash have been observed and have been short-lived. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme.

You should call your doctor if you experience any of these side effects or if any of these side effects are severe, get worse, or do not go away.

Select Important Safety Information

Contraindications

Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Please see the continued Important Safety Information below, and see the Pulmozyme full Prescribing Information for additional Important Safety Information.

Pediatric use of Pulmozyme® (dornase alfa) for cystic fibrosis (CF)

Pediatric Use

The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

See info for caregivers and parents

Remember to discuss side effects with your child’s doctor

Here are some questions to help get the conversations started

  • What is the most important information I should know about Pulmozyme? 
  • What should I do if I experience a side effect? 
  • What side effects are most common?
  • Which side effects are most serious?
  • Am I at higher risk for any specific side effects?
  • How long do side effects typically last?

Indication & Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.